Myasthenia Gravis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

NEW YORK, Feb. 8, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Myasthenia Gravis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

http://www.reportlinker.com/p0769439/Myasthenia-Gravis-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2019.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Myasthenia Gravis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, "Myasthenia Gravis Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Myasthenia Gravis Therapeutics market. The report identifies the key trends shaping and driving the global Myasthenia Gravis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Myasthenia Gravis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Scope

The report provides information on the key drivers and challenges of the Myasthenia Gravis Therapeutics market. Its scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Myasthenia Gravis Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.

- Analysis of the current and future competition in the seven key countries Myasthenia Gravis Therapeutics market.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Myasthenia Gravis Therapeutics market.

- Analysis of key recent licensing and partnership agreements in Myasthenia Gravis Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global Myasthenia Gravis Therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Myasthenia Gravis Therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global Myasthenia Gravis Therapeutics market landscape? - Identify, understand and capitalize.

1 Table of Contents1 Table of Contents 31.1 List of Tables 51.2 List of Figures 62 Myasthenia Gravis Therapeutics - Introduction 72.1 Disease Overview 72.2 Epidemiology 82.3 Etiology and Pathology 102.4 Signs and Symptoms 122.5 Diagnosis 122.5.1 Pharmacological Testing - There are two types of pharmacological tests 122.5.2 Serological Testing: 122.5.3 Electrophysiological Testing: 132.5.4 Imaging Tests: 132.6 Treatment and Management Pattern 142.6.1 Pharmacological Therapy 142.7 Referral Pathway 152.8 GlobalData Pipeline Report Guidance 163 Myasthenia Gravis Therapeutics - Market Characterization 173.1 Myasthenia Gravis Therapeutics Market Size (2006-2011) - Global 173.2 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - Global 183.3 Myasthenia Gravis Therapeutics Market Size (2006-2011) - The US 193.4 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - The US 203.5 Myasthenia Gravis Therapeutics Market Size (2006-2011) - France 213.6 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - France 223.7 Myasthenia Gravis Therapeutics Market Size (2006-2011) - Germany 233.8 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - Germany 243.9 Myasthenia Gravis Therapeutics Market Size (2006-2011) - Italy 253.10 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - Italy 263.11 Myasthenia Gravis Therapeutics Market Size (2006-2011) - Spain 273.12 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - Spain 283.13 Myasthenia Gravis Therapeutics Market Size (2006-2011) - The UK 293.14 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - The UK 303.15 Myasthenia Gravis Therapeutics Market Size (2006-2011) - Japan 313.16 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - Japan 323.17 Drivers and Barriers for the Myasthenia Gravis Therapeutics Market 333.17.1 Drivers for the Myasthenia Gravis Therapeutics Market 333.17.2 Barriers for the Myasthenia Gravis Therapeutics Market 333.17.3 Opportunity and Unmet Need Analysis 333.18 Key Takeaway 344 Myasthenia Gravis Therapeutics - Competitive Assessment 354.1 Overview 354.2 Strategic Competitor Assessment 354.3 Product Profiles of the Major Marketed Products in the Myasthenia Gravis Therapeutics Market 374.3.1 Acetylcholinesterase Inhibitor (pyridostigmine) 374.3.2 Steroids (prednisone) 384.3.3 Immunosuppressants 384.3.4 Azathioprine 384.3.5 Cyclosporin A 394.3.6 Mycophenolate Mofetil (MMF) 394.3.7 Venoglobulin-IH 404.4 Key Takeaway 405 Myasthenia Gravis Therapeutics - Pipeline Assessment 415.1 Overview 415.2 Strategic Pipeline Assessment 415.3 Myasthenia Gravis Therapeutics Pipeline - Pipeline by Phases of Development 415.3.1 Myasthenia Gravis Therapeutics - Phase III Pipeline 415.3.2 Myasthenia Gravis Therapeutics - Phase II Pipeline 425.3.3 Myasthenia Gravis Therapeutics - IND filed Pipeline 425.3.4 Technology Trends Analytic Framework 425.4 Myasthenia Gravis Therapeutics Market -Pipeline by Mechanism of Action 445.5 Myasthenia Gravis Therapeutics - Promising Drugs under Clinical Development 455.6 Molecule Profile for Promising Drugs under Clinical Development 455.7 Key Takeaway 456 Myasthenia Gravis Therapeutics - Clinical Trials Mapping 466.1 Clinical Trials by Region/Country (US, EU5 and Japan) 466.2 Clinical Trials by Phase 476.3 Clinical Trials by Trial Status 486.4 Prominent Sponsors 496.5 Top Companies Participating in Myasthenia Gravis Therapeutics Clinical Trials 517 Strategic Assessment 527.1 Key Events Impacting the Future Market 527.2 Myasthenia gravis Therapeutics: Implications for Future Market Competition 538 Myasthenia Gravis Therapeutics - Future Players 548.1 Company Profiles 548.2 Cytokinetics, Inc. 548.3 Alexion Pharmaceuticals, Inc 559 Myasthenia Gravis Therapeutics - Licensing and Partnership Deals 5610 Myasthenia Gravis Therapeutics - Appendix 5710.1 Market Definitions 5710.2 Abbreviations 5710.3 Methodology 5710.3.1 Coverage 5810.3.2 Secondary Research 5810.3.3 Forecasting 5810.3.4 Primary Research 6010.3.5 Expert Panel Validation 6110.4 Contact Us 6110.5 Disclaimer 6110.6 Bibliography 61

List of Tables

Table 1: Clinical Classification of Myasthenia Gravis According to Myasthenia Gravis Foundation of America (MGFA) 7Table 2: Prevalence of Myasthenia Gravis by Country (G7) 8Table 3: Myasthenia Gravis Quality of Life Questionnaire 9Table 4: Myasthenia Gravis Therapeutics Market, Global, Revenue ($m), 2006-2011 17Table 5: Myasthenia Gravis Therapeutics Market, Global, Forecast ($m), 2011-2019 18Table 6: Myasthenia Gravis Therapeutics Market, The US, Revenue ($m), 2006-2011 19Table 7: Myasthenia Gravis Therapeutics Market, The US, Forecasts ($m), 2011-2019 20Table 8: Myasthenia Gravis Therapeutics Market, France, Revenue ($m), 2006-2011 21Table 9: Myasthenia Gravis Therapeutics Market, France, Forecasts ($m), 2011-2019 22Table 10: Myasthenia Gravis Therapeutics Market, Germany, Revenue ($m), 2006-2011 23Table 11: Myasthenia Gravis Therapeutics Market, Germany, Forecasts ($m), 2011-2019 24Table 12: Myasthenia Gravis Therapeutics Market, Italy, Revenue ($m), 2006-2011 25Table 13: Myasthenia Gravis Therapeutics Market, Italy, Forecasts ($m), 2011-2019 26Table 14: Myasthenia Gravis Therapeutics Market, Spain, Revenue ($m), 2006-2011 27Table 15: Myasthenia Gravis Therapeutics Market, Spain, Forecasts ($m), 2011-2019 28Table 16: Myasthenia Gravis Therapeutics Market, The UK, Revenue ($m), 2006-2011 29Table 17: Myasthenia Gravis Therapeutics Market, The UK, Forecasts ($m), 2011-2019 30Table 18: Myasthenia Gravis Therapeutics Market, Japan, Revenue ($m), 2006-2011 31Table 19: Myasthenia Gravis Therapeutics Market, Japan, Forecasts ($m), 2011-2019 32Table 20: Myasthenia gravis Therapeutics, Phase III Pipeline, 2011 41Table 21: Myasthenia gravis Therapeutics, Phase II Pipeline, 2011 42Table 22: Myasthenia Gravis Therapeutics, IND Filed Pipeline, 2011 42Table 23: Myasthenia Gravis Therapeutics, Clinical Trials by Country, 2011 46Table 24: Myasthenia Gravis Therapeutics, Clinical Trials by Phase, 2011 47Table 25: Myasthenia Gravis Therapeutics, Clinical Trials by Status, 2011 48Table 26: Myasthenia Gravis Therapeutics, Prominent Sponsors, 2011 50Table 27: Myasthenia Gravis Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011 51Table 28: Cytokinetics, Inc., Pipeline, 2011 54Table 29: Alexion Pharmaceuticals, Inc., Pipeline, 2011 55

List of Figures

Figure 1: Normal Neuromuscular Junction 10Figure 2: Difference Between Normal and Myasthenic Neuromuscular Junctions 11Figure 3: Signs and Symptoms 12Figure 4: Repetitive Nerve Stimulation Electrical Tracing 13Figure 5: Referral Pathway 15Figure 6: Myasthenia Gravis Therapeutics Market, Global, Revenue ($m), 2006-2011 17Figure 7: Myasthenia Gravis Therapeutics Market, Global, Forecast ($m), 2011-2019 18Figure 8: Myasthenia Gravis Therapeutics Market, The US, Forecast ($m), 2006-2011 19Figure 9: Myasthenia Gravis Therapeutics Market, The US, Forecast ($m), 2011-2019 20Figure 10: Myasthenia Gravis Therapeutics Market, France, Revenue ($m), 2006-2011 21Figure 11: Myasthenia Gravis Therapeutics Market, France, Forecast ($m), 2011-2019 22Figure 12: Myasthenia Gravis Therapeutics Market, Germany, Revenue ($m), 2006-2011 23Figure 13: Myasthenia Gravis Therapeutics Market, Germany, Forecast ($m), 2011-2019 24Figure 14: Myasthenia Gravis Therapeutics Market, Italy, Revenue ($m), 2006-2011 25Figure 15: Myasthenia Gravis Therapeutics Market, Italy, Forecast ($m), 2011-2019 26Figure 16: Myasthenia Gravis Therapeutics Market, Spain, Revenue ($m), 2006-2011 27Figure 17: Myasthenia Gravis Therapeutics Market, Spain, Forecast ($m), 2011-2019 28Figure 18: Myasthenia Gravis Therapeutics Market, The UK, Revenue ($m), 2006-2011 29Figure 19: Myasthenia Gravis Therapeutics Market, The UK, Forecast ($m), 2011-2019 30Figure 20: Myasthenia Gravis Therapeutics Market, Japan, Revenue ($m), 2006-2011 31Figure 21: Myasthenia Gravis Therapeutics Market, Japan, Forecast ($m), 2011-2019 32Figure 22: Opportunity and Unmet Need in the Myasthenia Gravis Therapeutics Market, 2011 34Figure 23: Myasthenia Gravis Therapeutics, Strategic Competitor Assessment, 2010 36Figure 24: Myasthenia gravis Therapeutics - Pipeline by Phase of Development, 2011 41Figure 25: Myasthenia Gravis Therapeutics, Technology Trends Analytics Framework, 2011 43Figure 26: Myasthenia Gravis Pipeline, Technology Trends Analytics Framework, Description, 2011 43Figure 27: Myasthenia Gravis Therapeutics, Pipeline by Mechanism of Action, 2011 44Figure 28: Myasthenia Gravis Therapeutics, Clinical Trials by Country, 2011 46Figure 29: Myasthenia Gravis Therapeutics, Clinical Trials by Phase (%), 2011 47Figure 30: Myasthenia Gravis Therapeutics, Clinical Trials by Status (%), 2011 48Figure 31: Myasthenia Gravis Therapeutics, Overall Sponsors (%), 2011 49Figure 32: Myasthenia Gravis Therapeutics, Prominent Sponsors (%), 2011 50Figure 33: Myasthenia Gravis Therapeutics Market, Drivers and Restraints, 2011 52Figure 34: Implications for Future Market Competition in the Myasthenia Gravis Therapeutics Market, 2011 53Figure 35: GlobalData Market Forecasting Model 60

Companies mentioned

Cytokinetics, Inc.Alexion Pharmaceuticals, Inc

To order this report:Therapy Industry: Myasthenia Gravis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

More

Market Research Report

Check our

Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker